Business Context and Reporting Period
Company: HALOZYME THERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date: January 28, 2005
Jurisdiction: Nevada
Headquarters: San Diego, California
This filing serves as a Regulation FD disclosure to disseminate information regarding an investor presentation dated January 2005. The presentation slides are attached as Exhibit 99.1 and are intended for use with analysts and stockholders.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing to disclose the existence of an investor presentation rather than a financial statement containing quantitative performance data.
Material Changes
No material changes to financial position or operations are reported within the text of this Form 8-K. The filing references forward-looking statements and risks contained within the attached Exhibit 99.1 but does not detail specific operational changes in the main body.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing directs readers to page 2 of Exhibit 99.1 for a discussion of forward-looking statements and associated risks and uncertainties.
- Legal Disclaimer: The information furnished is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and will not be incorporated by reference into future registration statements unless specifically identified.
- Materiality: The report explicitly states it is not an admission as to the materiality of any information disclosed pursuant to Regulation FD.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Investor Presentation dated January 2005) for actual financial projections, strategic outlook, and specific risk factors.
- Verify the content of the investor presentation slides, as the 8-K only serves as a vehicle to distribute them.
- Note that the filing contains no audited financial data or specific operational metrics.